BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38146588)

  • 21. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
    Chen Q; Zheng PS; Yang WT
    Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian Carcinosarcoma and Concurrent Serous Tubal Intraepithelial Carcinoma With Next-Generation Sequencing Suggesting an Origin From the Fallopian Tube.
    See SHC; Behdad A; Maniar KP; Blanco LZ
    Int J Surg Pathol; 2019 Aug; 27(5):574-579. PubMed ID: 30913944
    [No Abstract]   [Full Text] [Related]  

  • 23. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
    Zhao S; Bellone S; Lopez S; Thakral D; Schwab C; English DP; Black J; Cocco E; Choi J; Zammataro L; Predolini F; Bonazzoli E; Bi M; Buza N; Hui P; Wong S; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Facchetti F; Falchetti M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Mane S; Angioli R; Terranova C; Quick CM; Edraki B; Bilgüvar K; Lee M; Choi M; Stiegler AL; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12238-12243. PubMed ID: 27791010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nuclear β-Catenin Expression in the Context of Abnormal p53 Expression Indicates a Nonserous Histotype in Endometrial Carcinoma.
    Keyhanian K; Yang EJ; Howitt BE
    Int J Gynecol Pathol; 2023 Sep; 42(5):435-442. PubMed ID: 36731035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An immunohistochemical panel of insulin-like growth factor II mRNA-binding protein 3 (IMP3), enhancer of zeste homolog 2 (EZH2), and p53 is useful for a diagnosis in bile duct biopsy.
    Sasaki M; Sato Y
    Virchows Arch; 2021 Oct; 479(4):697-703. PubMed ID: 34115196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors.
    Wassef M; Michaud A; Margueron R
    Cell Cycle; 2016 Sep; 15(17):2256-62. PubMed ID: 27419533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutational and Immunophenotypic Profiling of a Series of 8 Tubo-ovarian Carcinosarcomas Revealed a Monoclonal Origin of the Disease.
    Trento M; Munari G; Carraro V; Lanza C; Salmaso R; Pizzi S; Santoro L; Chiarelli S; Dal Santo L; Nardelli GB; Saccardi C; Nicoletto O; Baldoni A; Rugge M; Fassan M
    Int J Gynecol Pathol; 2020 Jul; 39(4):305-312. PubMed ID: 31688243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
    Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
    Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology.
    Jenkins TM; Cantrell LA; Stoler MH; Mills AM
    Am J Surg Pathol; 2022 Apr; 46(4):435-442. PubMed ID: 35125452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma.
    Abargel A; Avinoach I; Kravtsov V; Boaz M; Glezerman M; Menczer J
    Int J Gynecol Cancer; 2004; 14(2):354-9. PubMed ID: 15086737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
    Fadare O; Parkash V
    Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group.
    Woelber L; Prieske K; Eulenburg C; Oliveira-Ferrer L; de Gregorio N; Klapdor R; Kalder M; Braicu I; Fuerst S; Klar M; Strauss HG; Beckmann M; Meier W; Ignatov A; Mustea A; Jueckstock J; Schmidt G; Bauerschlag D; Hellriegel M; Canzler U; Petry KU; Kommoss S; Hantschmann P; Heubner M; Mahner S; Burandt E
    Am J Obstet Gynecol; 2021 Jun; 224(6):595.e1-595.e11. PubMed ID: 33453182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour.
    Schaefer IM; Hornick JL; Sholl LM; Quade BJ; Nucci MR; Parra-Herran C
    Histopathology; 2017 Jun; 70(7):1138-1146. PubMed ID: 28130839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
    Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
    Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
    Matsubara T; Toyokawa G; Takada K; Kinoshita F; Kozuma Y; Akamine T; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Mori M
    PLoS One; 2019; 14(5):e0215103. PubMed ID: 31042721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Association of the expression of p53 and p16INK4A with the clinical and morphological characteristicsof patients with head and neck squamous cell cancer].
    Stukan AI; Chukhray OY; Porkhanov VA; Bodnya VN
    Arkh Patol; 2019; 81(3):12-18. PubMed ID: 31317926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value.
    Meseure D; Vacher S; Alsibai KD; Nicolas A; Chemlali W; Caly M; Lidereau R; Pasmant E; Callens C; Bieche I
    Mol Cancer Res; 2016 Jul; 14(7):623-33. PubMed ID: 27102007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histologic Appearance and Immunohistochemistry of DNA Mismatch Repair Protein and p53 in Endometrial Carcinosarcoma: Impact on Prognosis and Insights Into Tumorigenesis.
    Saijo M; Nakamura K; Ida N; Nasu A; Yoshino T; Masuyama H; Yanai H
    Am J Surg Pathol; 2019 Nov; 43(11):1493-1500. PubMed ID: 31478942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical significance of expression of enhancer of zeste homolog 2 and 53 in cervical squamous cell carcinoma and intraepithelial neoplasia].
    Zhang H; Chen S; Niu G; Jiang H; Yao S
    Zhonghua Zhong Liu Za Zhi; 2014 Aug; 36(8):597-601. PubMed ID: 25430026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
    Chen L; Yang B
    Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.